ERBB2 and neoplasm: Despite moderate improvement in the OS of treated patients, both trastuzumab and anti-PD-1 therapies (nivolumab and pembrolizumab), targeting cell surface HER2 on cancer cells and PD-1 on immune cells of the tumor microenvironment, respectively, bear limited clinical efficacy due to the widespread emergence of tumor resistance [24].